The semaglutide supply situation in July 2026 is more complicated than the headlines suggest. The FDA's official drug shortage list tells one story. Provider websites tell another. And patient experience — whether your vial actually arrives on time — tells a third.
We investigated the current supply landscape by examining provider communications, pharmacy sourcing disclosures, and patient reports to build a picture of who actually has stock and who's relying on waitlists, substitutions, or creative workarounds.
The Supply Landscape in July 2026
The original semaglutide shortage — driven by explosive demand outpacing Novo Nordisk's manufacturing capacity — has largely resolved for the brand-name supply chain. Wegovy and Ozempic are available at most commercial pharmacies, and Novo Nordisk has expanded production capacity.
But the compounded semaglutide supply chain is a different story entirely. The FDA's regulatory actions around 503B outsourcing facilities have created a parallel supply disruption that affects telehealth providers disproportionately. Providers that sourced exclusively from 503B facilities are scrambling to establish 503A pharmacy relationships, and some are experiencing gaps.
What the 503B situation means for supply
503B outsourcing facilities can compound medications in bulk without individual patient prescriptions — which made them ideal high-volume suppliers for telehealth platforms. But FDA enforcement scrutiny has tightened. Some 503B facilities have received warning letters, had products recalled, or voluntarily reduced production to address quality concerns.
Providers that built their entire supply chain around one or two 503B facilities are now vulnerable. If their primary pharmacy reduces output or comes under FDA action, they don't have inventory. The providers with diversified pharmacy networks — multiple 503A relationships across different states — are better positioned.
What We're Seeing Across the Market
Providers with stable supply
Programs with diversified pharmacy partnerships — particularly those with multiple 503A compounding pharmacy relationships — are generally shipping on time. These providers invested in redundant supply chains specifically to avoid single-source risk. Their patients report consistent delivery timelines and reliable dose availability.
Providers with intermittent disruptions
A middle tier of providers is experiencing occasional delays, particularly at higher dose strengths (5 mg+). These programs may shift patients between pharmacies, substitute dose concentrations (requiring patients to adjust injection volumes), or extend the interval between shipments by a few days. Inconvenient but manageable.
Providers with significant delays
At the other end, some providers are waitlisting new patients for semaglutide entirely, steering existing patients toward tirzepatide as an alternative, or pausing operations until supply stabilizes. If you're considering a new program, ask explicitly whether semaglutide is available for immediate start or if there's a wait.
Tirzepatide as a Supply Hedge
An interesting dynamic in the supply conversation is tirzepatide. Because tirzepatide (the active ingredient in Zepbound and Mounjaro) is manufactured by Eli Lilly rather than Novo Nordisk, its supply chain is independent of the semaglutide situation. Some providers are positioning tirzepatide as a more reliable option — not because it's clinically superior for every patient, but because it's easier to source consistently.
If a provider recommends switching from semaglutide to tirzepatide, ask whether the recommendation is clinically motivated or supply-motivated. Both can be valid reasons, but you deserve to know which one is driving the conversation.
How to Protect Your Supply
- Ask about pharmacy sourcing before enrolling. How many pharmacy partners does the provider use? Are they 503A, 503B, or both? What happens if the primary pharmacy can't fill your order?
- Don't wait until you're out. If your provider ships monthly, contact them about your next shipment a week before you expect to run out. Early warning gives them time to solve supply issues before you face a gap.
- Keep one dose in reserve. If possible, maintain a small buffer so that a shipping delay doesn't mean an abrupt stop in treatment.
- Know your backup options. Identify one or two alternative providers that stock your medication at your current dose. If your primary provider experiences a prolonged disruption, you can transfer rather than wait.
These providers have demonstrated reliable supply chains through the current period:
Providers Worth Investigating
We evaluated these programs based on the criteria discussed in this article. Listings are paid partnerships — our analysis is independent.